Friday, 22 Mar 2019

You are here

Poor Prognosis of the MDA-5 Antibody in Dermatomyositis

Researchers from Hong Kong assessed the clinical associations seen with the anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) assay in consecutive patients with dermatomyositis (DM) and polymyositis (PM).

Twenty patients with either DM or PM who were followed in the Rheumatology Clinic of Kwong Wah Hospital, Hong Kong were recruited and underwent testing for the anti-MDA-5 antibody.

Anti-MDA5 Ab was found in 30% of patients with DM but not in DM patients. All patients with the antibody had clinically manifest amyopathic DM (CADM).  They were more likely to be male, younger and with shorter disease duration.

The MDA5 Ab profile identifies a subset of CADM with rapidly progressive interstitial lung disease (RP-ILD) and digital ulcers and was unaffected by treatment.

Another recent report from the American Journal of Medicine assayed 182 PM/DM patients for antiaminoacyl-tRNA synthetase (ARS) and MDA5 antibodies (Citation source https://buff.ly/2GC0EOG).

MDA-5 positive patients were more likely to have rapidly progressive ILD (RP-ILD) (55.8% vs. 25% versus 16.9%, P < 0.001) compared to those with ARS or without either antibody profile.

Whereas treatment responses and 5 year survival was poorest in the MDA5 group, the ARS patients had the best ILD improvement and survival (98% vs 50% in MDA5 group; P < 0.001).

MDA5-ILD patients are at risk for severe pulmonary manifestations, poor response to treatment and an unfavorable prognosis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Resistant Hypertension Common in SLE

Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.

Among patients with SLE, the prevalence of resistant hypertension was 10.2% compared with 5.3% among controls (OR 2.02, 95% CI 1.60-2.55, P<0.0001), according to Cecilia P. Chung, MD, and colleagues from Vanderbilt University in Nashville.

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.